Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
corifollitropin alfa
- Development stage
- Phase 4
- Lead developer
- Organon
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Corifollitropin alfa is a long-acting recombinant follicle-stimulating hormone (FSH) analog. It is designed for controlled ovarian stimulation (COS) in women undergoing assisted reproductive technology (ART) and for the treatment of hypogonadotropic hypogonadism in adolescent males. Its prolonged action, which allows for a single injection to replace multiple daily injections of conventional FSH, is achieved by fusing the C-terminal peptide of the beta-subunit of human chorionic gonadotropin (hCG) to the beta-chain of human FSH. This structural modification extends its half-life. Corifollitropin alfa acts as an agonist of the FSH receptor, stimulating the growth and development of ovarian follicles in women and promoting testicular growth and sperm production in males. It was originally developed by Organon/Schering-Plough and is currently marketed by Merck & Co. (MSD) in many countries.
- Brand names
- ElonvaJin SaijiaShengnuova
- Other names
- Follitropin-stimulating hormone long-actingFSH long-actingLong-acting follicle-stimulating hormoneCorifolitropina alfa
02
Targets
FSHR (Follicle-stimulating hormone receptor)
Beyond the preview
Go deeper on corifollitropin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on corifollitropin alfa.